Cadrenal Therapeutics
CVKD
10 hedge funds and large institutions have $1.04M invested in Cadrenal Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
154% more capital invested
Capital invested by funds: $408K → $1.04M (+$628K)
67% more funds holding
Funds holding: 6 → 10 (+4)
0.42% more ownership
Funds ownership: 0.28% → 0.71% (+0.42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$791K |
| 2 |
Renaissance Technologies
New York
|
+$58.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$47.2K |
| 4 |
VF
Virtu Financial
New York
|
+$27.4K |
| 5 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$23.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $823K | +$791K | +62,353 | +226% |
|
|
2
Renaissance Technologies
New York
| $90K | +$58.4K | +4,603 | +87% |
|
|
3
Citadel Advisors
Miami,
Florida
| $34.1K | +$47.2K | +3,723 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $26.1K | +$3.49K | +275 | +11% |
|
|
VF
5
Virtu Financial
New York
| $20K | +$27.4K | +2,159 | New |
|
|
APP
6
Avantax Planning Partners
Dubuque,
Iowa
| $17.3K | +$23.9K | +1,887 | New |
|
|
XT
7
XTX Topco
George Town,
Cayman Islands
| $12K | +$16.7K | +1,316 | New |
|
|
BFO
8
Biltmore Family Office
Charlotte,
North Carolina
| $6.71K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $5.81K | +$876 | +69 | +12% |
|
10
Wells Fargo
San Francisco,
California
| $33 | – | – | – |
|
CVKD Hedge Fund Activity: Q1 2024 in Review
10 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q1 2024, worth a combined $1.04M — up 154% from $408K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CVKD positions and 0 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, adding an estimated $791K.
- 10 institutional investors held Cadrenal Therapeutics (CVKD) as of Q1 2024, up from 6 in Q4 2023.
- Funds reported $1.04M of Cadrenal Therapeutics stock for Q1 2024, up 154% quarter-over-quarter.
- 4 funds opened new Cadrenal Therapeutics positions in Q1 2024 and 0 closed out, a net change of +4 holders.
- The largest Cadrenal Therapeutics buyer in Q1 2024 was Armistice Capital, an estimated $791K added.
Based on aggregated 13F filings for Q1 2024.